EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys



Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys



Antimicrobial Agents and ChemoTherapy 43(2): 381-384



The values of the pharmacokinetic parameters of the nucleoside antiretroviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D-D4FC) in rhesus monkeys were determined with a two-compartment model after the administration of a single dose. The average values for the terminal half-life, renal clearance, and total systemic clearance for the intravenous administration route were 3.6 h and 0.31 and 0.43 liter cntdot kg-1 cntdot h-1, respectively. The oral bioavailability of D-D4FC averaged 41%. For the intravenous administration route, 76% of the compound was recovered intact in the urine within 8 h, indicating that D-D4FC was eliminated mainly by renal excretion. D-D4FC was detected in the cerebrospinal fluid (CSF) at similar concentrations after administration by both the intravenous and oral routes. D-D4FC levels in plasma and CSF were higher than the median effective concentration for human immunodeficiency virus type 1 in vitro.

(PDF emailed within 1 workday: $29.90)

Accession: 011137979

Download citation: RISBibTeXText

PMID: 9925539



Related references

Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrobial Agents and ChemoTherapy 49(7): 2589-2597, 2005

Pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in rhesus monkeys. Antiviral Research 37(3): A47, March, 1998

Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys. Antimicrobial Agents and ChemoTherapy 49(2): 560-564, 2005

Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. Antimicrobial Agents and ChemoTherapy 43(4): 920-924, 1999

Studies of the pharmacokinetics and toxicology of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) in vivo; and synthesis and antiviral evaluations of 2',3'-dideoxy-beta-L-5-azacytidine. Nucleosides and Nucleotides 14(3-5): 619-625, 1995

Studies of the pharmacokinetics and toxicology of 2,3-dideoxy-beta-L-5-fluorocytidine and 2,3-dideoxy-beta-L-cytidine in vivo; and synthesis and antiviral evaluations of 2,3-dideoxy-beta-L-5-azacytidine. Nucleosides & Nucleotides 14(3-5): 619-625, 1995

Preclinical pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in woodchucks. Pharmaceutical Research (New York) 14(11 SUPPL ): S73, 1997

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrobial Agents and ChemoTherapy 45(4): 1065-1077, 2001

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrobial Agents and ChemoTherapy 44(1): 111-122, 1999

2,3-Dideoxy-2,3-didehydro-beta-L-5-fluorocytidine exhibits a more potent antiviral effect than lamivudine in chronically WHV infected woodchucks. Hepatology 30(4 PART 2): 344A, 1999

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Design and synthesis of 2,3-dideoxy-2,3-didehydro-beta-L-cytidine and 2,3-dideoxy-2,3-didehydro-beta-L-5-fluorocytidine , two exceptionally potent inhibitors of human hepatitis B virus and potent inhibitors of human immunodeficiency virus in vitro. Journal of Medicinal Chemistry 39(9): 1757-1759, 1996

Treatment of HIV by administration of beta-D-2, 3-didehydro-2,3-dideoxy-5-fluorocytidine. Official Gazette of the United States Patent & Trademark Office Patents 1246(3), May 15, 2001